adiso therapeutics

Adiso Therapeutics, Inc. is an innovative, private, clinical-stage biopharmaceutical company dedicated to improving the health of patients suffering from debilitating intestinal and inflammatory diseases with significant unmet need. This dedication is epitomized by our lead clinical candidates, ADS051 an oral gastrointestinal restricted modulator of neutrophil trafficking for the treatment of ulcerative colitis, and ADS032 a novel dual NLRP1 / NLRP3 inflammasome inhibitor initially being developed for inflammatory diseases of the lung, with additional programs targeted for dermatologic and other inflammatory disorders. Adiso has built these development programs upon a rich history of institutional and academic collaboration, including the University County Cork, Ireland, University of Massachusetts Chan Medical School and the Hudson Institute Melbourne AUS. Find our more at www.adisotx.com